Antibiotics · 2023 · 24 citations · 19 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyCardiovascular PharmacotherapyAntibacterial PharmacotherapyEmpiric Antimicrobial TherapyInfection ManagementInfective EndocarditisTreatment Of EndocarditisBactericidal AgentsBiofilm Drug PenetrationCardiac Implantable DevicesCardiac Implantable Electronic Device InfectionDuration Of Antimicrobial TreatmentEndocarditis After Valve ReplacementIntracardiac Device-related EndocarditisSequential Therapy Duration
Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is limited, and only a few cases have performed therapeutic drug monitoring (TDM) analysis to optimize dosage in suppressive treatments longer than 4 weeks. Our retrospective case series reports the use of dalbavancin in a small cohort of patients with cardiovascular prosthetic infections (cardiac implantable electronic device infections (CEDIs), prosthetic valve endocarditis (PVE), prosthetic vascular graft infections (PVGIs)) treated with dalbavancin as sequential therapy. From May 2019 to May 2023, 14 patients were included: eight cases of PVE (57.1%), seven cases of PVGI (50%), three cases of CEDI (21.4%), and four cases with overlap of infection sites (28.6%). The main pathogen was Staphylococcus aureus (35.7%). Prosthesis replacement was obtained in four patients (28.6%). The median time between symptom onset and the end of treatment was 15 weeks (IQR 7-53), with a median duration of dalbavancin therapy of 8 weeks (IQR 1 to 45 weeks) and 3.5 doses per patient. Among patients managed with TDM-guided strategy, dalbavancin infusion intervals ranged from 4 to 9 weeks. The median length of follow-up was 65 weeks (IQR 23 to 144 weeks). Clinical success was achieved in 10 cases (76.9%); all clinical failures occurred in patients with the implant retained. Among patients monitored by TDM, clinical success was 87.5% vs. 60% in patients treated without TDM. Because of pharmacokinetic individual variability, dalbavancin TDM-guided administration could improve clinical outcomes by individualizing dosing and selecting dosing intervals. This case series seems to suggest a promising role of long-term suppressive dalbavancin treatment for difficult-to-treat cardiovascular prosthesis infection, also with limited surgical indications.
19
2015 ESC Guidelines for the management of infective endocarditis
Gilbert Habib, Patrizio Lancellotti, Manuel J. Antunes et al. · European Heart Journal · 2015 · 5K citations · Full text
2023 ESC Guidelines for the management of endocarditis
Victoria Delgado, Nina Ajmone Marsan, Suzanne de Waha et al. · European Heart Journal · 2023 · 1.6K citations · Full text
Thomas J. Cahill, Bernard Prendergast · The Lancet · 2015 · 973 citations
Michael W. Dunne, Sailaja Puttagunta, Philip Giordano et al. · Clinical Infectious Diseases · 2015 · 214 citations · Full text